Xaluritamig plus abiraterone shows promising anti-tumour activity with manageable safety in chemotherapy-naïve mCRPC

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC

miR371 shows promise as a surveillance biomarker for relapse in early-stage germ cell tumours

Implanted tile-based radiation shows promise compared with stereotactic radiotherapy for brain metastases

Lorlatinib delivers 7-year progression-free survival and durable brain control in ALK+ NSCLC

Low-dose pembrolizumab plus chemotherapy improves survival and expands access in advanced NSCLC

ASCO 2026: Latest updates in mRCC

Adagloxad simolenin plus OBI-821 shows no survival benefit compared to standard of care in triple-negative breast cancer

ASCO 2026: Breast cancer overview

mRNA-4359 plus pembrolizumab shows high response rates and robust T-cell activation in melanoma

Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?

Part 1: Why test?